Primary cutaneous marginal zone lymphoproliferative disorder following COVID‐19 vaccination

Abstract

AbstractDuring the coronavirus disease 2019 (COVID‐19) pandemic, COVID‐19 vaccines were administered worldwide. A number of skin reactions, including primary cutaneous T‐cell lymphoproliferative disorders (LPDs) were reported following COVID‐19 vaccination. We report a case of primary cutaneous marginal zone lymphoproliferative disorder (PCMZLPD) secondary to COVID‐19 vaccination. A 57‐year‐old man presented with an erythematous nodule on his left arm at the site of vaccine inoculation following his first dose of the Moderna (mRNA‐1273) vaccine a few weeks prior. The nodule continued to progress in size after the second dose. A skin biopsy specimen of the nodule showed a diffuse dermal infiltrate of small to medium‐sized lymphocytes with plasma cells and histiocytes. The infiltrate was composed of CD3+ T cells with CD20+ and CD79a+ B cells. The neoplastic B cells reacted with BCL‐2 and were negative for BCL‐6 and CD10. Kappa light chain restriction was identified by in situ hybridization. Gene rearrangement studies revealed kappa light chain monoclonality, confirming the diagnosis of PCMZLPD. The temporal association with the Moderna vaccination and the occurrence of the lesion at the inoculation site indicate a COVID‐19 vaccination‐induced PCMZLPD. This is one of the rare cases of PCMZLPD following COVID‐19 vaccination.